Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Fertility DX has arrived. Genetic fertility scanning for female, male and baby. Complete family package!
https://www.predictivelabs.com/fertilitydx
You’re completely wrong as the nyse uplist criteria is much stricter. Also if you read my post you would realize that going to QX/QB has no negative impact on Nasdaq as they are completely separate processes and as such apart from some people trying to say it’s bad, there is no other negatives and to be honest what is said is irrelevant.
Also re Nasdaq, it’s a process, if the company easy refused or withdrew its application, it has 3 days to report that. No news means things are moving along, the only issue was people’s BS expectations.
Endometriosis. None
This is the secret sauce which allows them to offer endo test in conjunction with the other available tests in an all inclusive package.
Their next gen products are even more detailed. Fertility DX is a thing of beauty
You’re dealing with a company that is doing 50m in revenue. 16k for an otc uplist is irrelevant and as for time, as I’ve stated, it doesn’t inhibit the Nasdaq move in any way and doesn’t impact in the company’s time so why not do it? Can you show me a negative apart for some uneducated jumping up and down about “o there must be an issue with Nasdaq” BS? (Jumping up and some not aimed at you )
In this case your (and Thomas’s) assessment is incorrect. There is zero downside to going up to a higher exchange with more transparency. Bit like adding Deloitte to the roster, small positives steps lead to big outcomes.
Going to QB/QX does not effect the Nasdaq process in any way so why not do it? I know I’d be a lot happier if we were in QB/QX now as opposed to “Nasdaq next week” that that has been going on for months.
Rule 101, make it easy for people to help you. This move if it happens makes it easier for Nasdaq and is a positive step
Stock boy, re your message. You’re 100% wrong
I respectfully beg to differ as it’s much easier for nasdaq to be seen to uplist an QX/QB company instead of a pink. They are separate things anyway, one does not impact the timing of the other. Company could be nasdaq next week and the conversation is mute. If they do uplist to QB/QX it has zero negative effect on Nasdaq as their process is set and running.
By all means explain why you disagree as any step forward to ease the way to nasdaq would have to be positive.
Also re the US numbers, the asrm conference will be attended by 9000 fertility doctors! Seems to be a good idea re their launch of Artguide and their other fertility products. All that from a guest speaker presentation platform!!
There are multiple tests in the market, what makes pred unique is the endometriosis component which is protected under patent. Endo is a huge problem in its own right so it’s obvious that any women looking for a fertility overview would want to cover this and use the test.
Re cost, I believe it’s north of $1500 per test which in the land of fertility is a tiny cost. Margins are incredible I believe and as you can imagine won’t be discussed with us!
What people don’t get is that the numbers Thomas eluded to are for the US market . The worlds a big place! Same medical issues everywhere.
Also this is just on art guide , what about fertility DX which offers a first in class genetic mapping for the family.
As I’ve always said, this is not a stem cell company and you are now seeing a pivot towards where the true future of the company is.
Re the QX debate, it makes perfect sense, it’s a forward step towards nasdaq,
QX would not be the destination but part of the journey to nasdaq. If they do go down that route, then I believe it’s smart and a great step
Year 1 per their presentation $150m, year 2 $450m
Breaking news
Predictive Laboratories Announces Commercialization And Full Market Availability Of ARTguide™ At American Society Of Reproductive Medicine (ASRM) Scientific Congress And Expo
Again waiting on the neutral explanation.
How can hiring and being accepted by one of the top 4 auditors worldwide be neutral?
1. Deloitte wouldn’t accept them without a thorough review
2. I’m sure nasdaq are happier with Deloitte
3. If you’re going to do business worldwide you need a worldwide auditor as a regional auditor wouldn’t suffice,
I await your learned reply
This will be good.
Go ahead and give us the 3 versions
Another box ticked
8k Item 4.01 Changes in Registrant’s Certifying Accountant
On October 7, 2019, the Company’s Board of Directors elected to retain Deloitte & Touche LLP (”Deloitte”) as its independent registered public accounting firm in place of BF Borgers CPA PC (“Borgers”). The decision to change independent registered public accounting firms was recommended by the Company’s Audit Committee and approved by its Board of Directors.
The reports of Borgers on the June 30, 2019 and 2018 financial statements of the Company, did not contain any adverse opinion or disclaimer of opinion and were not qualified or modified as to uncertainty, audit scope or accounting principles. During the Company’s two most recent fiscal years and all subsequent interim periods preceding such change in auditors, there was no disagreement with Borgers on any matter of accounting principles or practices, financial statement disclosure, or auditing scope or procedure, which, if not resolved to the satisfaction of the former accountant, would have caused it to make a reference to the subject matter of the disagreements in connection with its report; nor has Borgers ever presented a written report, or otherwise communicated in writing to the Company or its board of directors the existence of any “disagreement” or “reportable event” within the meaning of Item 304 of Regulation S-B.
The Company has authorized Borgers to respond fully to the inquiries of Deloitte, and Borgers has provided the Company with a letter addressed to the SEC, as required by Item 304(a)(3) of Regulation S-B, that is attached hereto as Exhibit 16.1.
Most undervalued stock in the market. Going green green green
[/October is going to start heating up for $PRED
-Launch of FertilityDX
-More commercialization growth of PGxPLUS+
-Three huge presentations of new genetic findings in endometriosis at the (ASRM) Scientific Congress & Expo being held October 12-16.
globenewswire.com/news-release/2…b]
Thermo Fisher know where the action is !
https://youtu.be/IK3DxVveDlw
FYI last paragraph in the PRED TMO is the same lady and interesting connect
“We look forward to this exciting and important work with Predictive Laboratories to better understand infertility in women,” said Yan Zhang, general manager, reproductive health at Thermo Fisher. “With the combination of our partner’s expertise and our advanced solutions for genetic analysis, we are committed to reducing the future financial and emotional burden couples face while undergoing fertility treatment.”
http://predtechgroup.com/2019/06/thermo-fisher-scientific-and-predictive-laboratories-announce-global-infertility-research-collaboration/
most are missing the point
Go read the press over the last year. Stem cell revenue being up isn’t the point. The future is the diagnostics, therapy’s and the use of their platform.
To date we know of endometriosis, preeclampsia, joint treatment, pain management plus much much more. Life sciences companies that have one all or nothing potential products trade at billions of dollars yet pred has multiple routes to market.
Add in the world class science team, world class board, world class attorneys and then you will understand where this is going.
As Thomas alluded to earlier in the week, the value here is the patents and their platform. Everyone wants instant gratification as that’s the story of the otc and how 95% of everyone is. This is a growing company doing good increasing revenues, cash flow positive with an incredible pipleline and because price is depressed the “management” aren’t doing their job keeping people on a message board happy! That’s not their job no matter how important we all think we are.
This company is substantially better now than it was at $6 but I didn’t hear anyone at $6 saying management are doing a terrible job! Nope, everyone caught up in the euphoria and patting themselves on the baby. The company doesn’t control share price, they control the fundamentals l.
They have released 27 pieces of fantastic news over the last nine months, yet most on here are still talking about stem cells. Go do some work and actually read them, you may surprise yourself and learn something
PRED's management team:
By now, nearly everyone on this board must be familiar with the stellar resumes of PRED's management team.
As long as we're waiting for things to take off, take another look at these individuals running things at PRED. (pulled directly from the 10K released yesterday) Also look at how these same individuals are being compensated with shares of PRED. (also in the 10K) Now factor in how not a single one of these individuals sold a single share, even when the stock price recently went up to just shy of $7. Pump and dump? Not a chance.
There's no other conclusion to come to other than these experienced, seasoned leaders have complete faith in PRED and the direction it is heading. Why else would they leave lucrative, safe, respected positions in well-established companies to come over to upstart PRED? There's no other logical reason, unless they were 100% believers.
BIOGRAPHY
John Sorrentino was elected as Chairman of the Board in October of 2018. Mr. Sorrentino served as Vice President & Chief Operating Officer, Pfizer Vaccine Research & Development, until his retirement in April 2019. At Pfizer, Mr. Sorrentino was responsible for the strategic deployment and management of financial, physical and human resources across nine vaccine research & development sites in seven countries. Mr. Sorrentino manages a broad mix of financial, facility, staffing clinical testing and systems initiatives to support the vaccine portfolio. These efforts span the entire research and development life cycle from early-stage discovery projects through product-registration activities. Mr. Sorrentino was a member of the leadership team that developed and licensed Prevnar 13, the most commercially successful vaccine franchise in history. In his role with Pfizer, Mr. Sorrentino also managed clinical laboratory services and developed staffing, capital, contracting and other assay-strategies required to assess human immune responses to vaccine candidates and to support vaccine label claims. As Pearl River Site Head, Mr. Sorrentino managed a broad spectrum of site operations. He directed external communications, community relations, colleague enrichment/engagement, diversity and other site-related programs. Mr. Sorrentino has more than 35 years of senior management experience in the life-sciences. He has held leadership roles in private and public companies as well as government and non-profit institutions focused on improving the public health. Prior to joining Wyeth/Pfizer in 2003, Mr. Sorrentino held executive management positions in several organizations that provided neonatal screening and related clinical services. In these roles, Mr. Sorrentino pioneered laboratory advances to create efficiency and competitive advantage that led to the expansion of neonatal screening for treatable genetic conditions throughout the world. During his career, Mr. Sorrentino has held final profit and loss responsibility for several organizations and he has been a founder of three companies. He has led mergers and acquisitions and developed successful exit strategies for founders. Mr. Sorrentino has also been a registered lobbyist appearing before state legislators, the US congress and professional societies on a variety of health care and other policy issues. Mr. Sorrentino earned his BA in Chemistry from the University of Massachusetts and MBA from Northeastern University.
The Board of Directors has determined that Mr. Sorrentino’s extensive business and leadership experience in the life sciences industry qualifies him to serve as a member of our Board of Directors.
Mr. Ron Barhorst has been a director since March 2019. Mr. Barhorst worked for ING and ING’s predecessor companies for 25 years. During his tenure he held a broad array of roles. Most recently Mr. Barhorst was the President and CEO of three (3) broker dealers; ING Financial Advisers, LLC, ING Investment Advisors, LLC, and Systematized Benefits Administrators, Inc. He was also the head of ING’s financial advisory business in the US. Mr. Barhorst retired from ING on December 31, 2012. His early career with ING was dedicated to the development of the qualified retirement plan market. Ron’s roles included Regional Manager, District Manager, Regional Vice President and National Head of Health, Education, and Government Sales. Much of his career included appointments to various company boards, and executive level committees. He was also responsible for a large portion of ING’s U.S. based securities registered representative distribution.
-85-
Prior to joining ING, Ron worked as the Head of Residential Services for the Montgomery County (Ohio) Board of Mental Retardation and Developmental Disabilities and was a member of the Governor’s council on deinstitutionalization. Ron created a not-for-profit company, Choices in Community Living, Inc., where he served as the Executive Director. Ron has served on numerous not-for-profit boards including the California Business Roundtable for Education Excellence. He is currently the Chairman of the California State University Board of Governors (system wide foundation) and head of the Executive Committee. Ron has held Chairmanship for the past ten (10) years and has been a member of the board since 2000. Ron is a 1982 graduate of Wright State University and holds a degree in Biology. Ron and his wife, Mitzi, who is also a 1982 graduate of Wright State University, live in Waterford Connecticut.
The Board of Directors has determined that Mr. Barhorst’s extensive business and leadership experience on several board of directors and financial expertise qualifies him to serve as a member of our Board of Directors.
Senator Orrin G. Hatch has been a director since February 2019. Senator Hatch is an attorney and retired politician who served as a U.S. Senator from Utah for 42 years. First elected in 1976, he was the longest-serving Republican U.S. Senator in history. Senator Hatch served as either the chair or ranking minority member of the Senate Judiciary Committee from 1993 to 2005. He previously chaired the Senate Committee on Health, Education, Labor, and Pensions from 1981 to 1987. Senator Hatch also served as Chairman of the Senate Finance Committee. On January 3, 2015, after the 114th United States Congress was sworn in, Hatch became President pro tempore of the Senate. Senator Hatch retired from the U.S. Senate in 2019.
The Board of Directors believes Senator Hatch is qualified to serve on our Board of Directors due to his seven terms as a U.S. Senator, including service as a member or chair of various U.S. Senate committees.
Mr. Jay Moyes has been a director since February 2019. Mr. Moyes previously served as Chief Financial Officer and Director of the publicly traded biomaterials company Amedica Corporation, now SINTX Technologies, where he managed the company's IPO and listing on NASDAQ, and as Chief Financial Officer at publicly traded CareDx, a molecular diagnostics company where he introduced a strategy to reach profitability. Prior to that he held senior finance positions including Chief Financial Officer during his 14-year tenure at publicly traded Myriad Genetics. In addition to overseeing all financial aspects at Myriad as the company transitioned from 10 to more than 900 employees, he was instrumental in raising more than $500 million in public and private financings. He previously was Vice President of Finance and Chief Financial Officer of Genmark, a private genetics company. Mr. Moyes began his career in public accounting at KPMG and serves on the Boards of Directors of Achieve Life Sciences (NASDAQ:ACHV), BioCardia (OTC/QB: BCDA) and Puma Biotechnologies (NYSE:PBYI). In addition to Amedica, he previously was a director and Chairman of the Audit Committee of both Osiris Therapeutics (NASDAQ:OSIR) and Integrated Diagnostics. He also served as a member of the Board of Trustees of the Utah Life Science Association. Mr. Moyes holds a BA in economics from Weber State University and an MBA from the University of Utah.
The Board of Directors believes Mr. Moyes is qualified to serve on our Board of Directors due to his extensive experience in the life sciences industry, his broad leadership experience with Myriad Genetics and on several boards of life science companies, and his experience with financial matters.
-86-
Mr. Bradley Robinson was appointed CEO of Predictive Technology Group, Inc. in March, 2015. Mr. Robinson brings operational, business development and financing experience to Predictive Technology Group, Inc. The majority of this experience was developed during early stage structuring of ventures in the areas of pharmaceuticals, medical device and information technology. He was a founding member of LifeCode Genetics, LLC in 2011 and Predictive Therapeutics, LLC in 2013, both of which are now wholly owned subsidiaries of the Company. Mr. Robinson has been a founding member of other ventures in healthcare, one of which, Specialized Health Products International, Inc., was publicly traded until its acquisition in March of 2008 by C.R. Bard. Mr. Robinson was the CEO and co-founder of Infusive Technologies, LLC from November, 2004 until September, 2008 when it was acquired by Sagent Pharmaceuticals, Inc., a specialty injectable pharmaceutical products company. As part of the acquisition, Mr. Robinson became President of the medical device division of Sagent Pharmaceuticals. He left Sagent Pharmaceuticals in 2010 to become Vice President of Business Development of Juneau BioSciences, which develops and commercializes genetic tests related to women’s healthcare. He was responsible for developing strategic partnerships and the company’s capitalization. Mr. Robinson studied accounting at the University of Utah and earned an MBA/MIM from the Graduate School of International Management (Thunderbird).
The Board of Directors believes Mr. Robinson’s extensive leadership, executive, managerial, business and healthcare industry experience qualifies him to serve as a member of our Board of Directors. In addition, Mr. Robinson’s day-to-day management and intimate knowledge of our business and operations provide our Board with an in-depth understanding of the Company.
Mr. Michael Dey, Ph.D., was elected as a member of the Board of the Company and CEO of Predictive Therapeutics, a wholly-owned subsidiary of the Company, in June of 2016. Prior to joining Predictive Therapeutics, Dr. Dey was an executive at Wyeth where he was the President of Scientific Affairs for Wyeth’s Women’s Health Care business. Prior, Dr. Dey was the President of Wyeth Women’s Health Care which he managed for 7 years. Dr. Dey had worldwide responsibility for this consolidated unit of more than $3 billion annually that included all of Wyeth’s Women’s Health Care resources globally. Prior to his leadership role in women's health care he served as Vice President, General Manager of ESI Pharma, Inc. In 1995, with Wyeth’s acquisition of American Cyanamid and Lederle Standard Products, Dr. Dey became President of ESI Lederle, Inc. As President of ESI Lederle, his responsibilities included directing one of the largest generic drug companies in the U.S. with more than $500 million in sales, approximately 150 employees in R&D and 100 employees in Marketing and Sales. ESI Lederle sold both oral and injectable products that included Tubex®, the prefilled syringe delivery system. Dr. Dey received a BS in Biology/Chemistry from Western Washington University, an MS degree in Pharmacology-Toxicology from the University of California, Davis, and a PhD in Pharmacology-Toxicology from Washington State University.
The Board of Directors believes that Dr. Dey is qualified to serve on our Board of Directors due to his extensive experience within the field of drug discovery and development, his broad leadership experience on various boards, and his financial expertise with life sciences companies.
Mr. Simon Brewer, CPA, was appointed to the Company’s Chief Accounting Officer in January of 2018, and Chief Financial Officer in July of 2018. Prior to joining our Company, Mr. Brewer served as Chief Financial Officer of Norbest, LLC from 2016 to 2017, where he was responsible for Norbest’s finance, accounting, HR and IT functions. Prior to joining Norbest, Mr. Brewer was Vice President, Finance and IT for Wilson Electronics, LLC from 2013 to 2016. Reporting directly to the CEO of Wilson Electronics, Mr. Brewer oversaw significant growth for the electronics company operating in all 50 states and internationally in several countries. Mr. Brewer assisted heavily in building scalable processes, modernizing the business, international growth in Asia, and an acquisition of a main competitor. Before that, he was Senior Director and Corporate Controller for Backcountry.com, Inc. from 2009 to 2013. Mr. Brewer implemented Sarbanes Oxley when Backcountry.com was purchased by a publicly traded Company, Liberty Interactive, as well as started the FP&A function for modernizing data driven decision making. Mr. Brewer started his accounting career as a CPA for KPMG LLP from 2005 to 2009, working on audits, IPOs, bankruptcies, divestitures, and acquisitions. Mr. Brewer received his BA and Masters of Accounting degrees, along with a minor in Russian, from The University of Utah. Mr. Brewer is a CPA licensed in Utah and Nevada.
-87-
Mr. Paul Evans was appointed Chief Operating Officer in June of 2018. Prior to joining the Company, Mr. Evans was Vice President of Intellectual Property at Vivint, Inc. from 2014 to 2015, where he led the development, management, and enforcement of Vivint’s intellectual property portfolio across the company’s entire platform of smart home solutions, including security and surveillance, smart home control, wireless internet, and cloud storage. From 2010 to 2013, Mr. Evans was General Counsel, Executive VP of Corporate Development, and Chief Governance and Compliance Officer at InTouch Health, a leading provider of telehealth enterprise network and managed services to hospitals and healthcare systems for the delivery of specialty clinical care to patients. Prior to joining InTouch Health, Mr. Evans was an attorney with Stoel Rives LLC from 2008 to 2010. From 2000 to 2008, he was General Counsel, VP of Business Development, Chief Governance and Compliance Officer of Specialized Health Products International, Inc., a medical device company acquired by C.R. Bard in 2008. Mr. Evans earned his BS in Mechanical Engineering, JD, and MBA degrees from The University of Utah.
Mr. Eric Olson is Executive Vice President, and the founder and Chief Executive Officer of Predictive Biotech, Inc., since he joined the Company in 2016. His previous experience includes over 25 years developing and commercializing innovative technologies in devices, diagnostics, biologics and biomaterials. The last 8 years of his career, Mr. Olson has served in the role of either President, Chief Executive Officer or Board Member. Prior to joining Predictive Technology Group, Mr. Olson was the President and CEO for Cupertino, CA based Skeletal Kinetics. This Colson & Associates company developed and commercialized synthetic bone substitute products for Orthopedic and Spinal applications. Previous to that, Mr. Olson was the President, CEO and Board Member for Amedica Corporation. Amedica manufactured and distributed cortical and cancellous silicon nitride ceramic interbody devices for spine. In addition, the company distributed a line of HCT/Ps designed to work in conjunction with the ceramic biomaterial. Mr. Olson took Amedica Corporation public in 2014. Mr. Olson began his career with Smith & Nephew and has worked with Johnson & Johnson, Medtronic and Wright Medical in Sales and Marketing leadership roles. Mr. Olson earned his BS in Behavioral Science and Health Administration degrees from The University of Utah.
Mr. Michael Herbert was appointed Chief Marketing Officer in February of 2017. Prior to joining our Company, Mr. Herbert was Chief Marketing Officer at Flagship Health Group 2011 to 2017, where he worked with many of the top insurers on their go-to-market strategies. Mr. Herbert’s focus has been on strategic brand building, channel alignment, product development and positioning across a broad spectrum of health care and consumer companies. He has held senior leadership and ownership positions in early through mid stage companies, including Bianchi (SVP Sales and marketing 1984 – 1996), Castelli (CEO, 1996 – 2004), Shock Doctor (Chief Sales and Marketing Officer 2004 – 2009), and DreamGuard (Chief Sales and Marketing Officer 2009 – 2011), leading to multiple successful transactions.
Most undervalued stock in the market. Going green green green
[/October is going to start heating up for $PRED
-Launch of FertilityDX
-More commercialization growth of PGxPLUS+
-Three huge presentations of new genetic findings in endometriosis at the (ASRM) Scientific Congress & Expo being held October 12-16.
globenewswire.com/news-release/2…b]
Think Themis post says it all really. Rom somebody who knows the space and the people
Stock green . Fun times ahead. Let’s all catch up in a few weeks when we are heading towards the highs again. Wonder who will be talking then
In the short to medium term. Too many people with unrealistic timelines fee by BS in message boards and “ people they know”! Company executing, future is bright so it’s hust sit and watch if people have the stomach for it. Hanging around message boards never made a stock go up or down. Just so r lowlifes playing in people’s naive emotions which is never nice to see
It’s all on the way. Hang in there and let’s see how you cope with it all when stock changes direction
most undervalued stock in the entire market
BEST POST EVER! Honest and what we all want to occur.
patience_in_waiting Tuesday, 10/01/19 03:36:34 PM
Re: happy gylmore post# 15436 0
Post #
15442
of 15548
I still believe everything is going to happen more or less all at once - a couple of major PRs (including at least one Hong Kong deal), the Oct 12-16 ASRM conference, (where PRED is going to educate the world), the Artguide launch, and the NASDAQ uplist.
The financials release yesterday were fantastic for a company that has yet to kick things into gear.
PRED is done messing around with any shorts, and potential hit pieces.
When PRED makes its move, it will be swift, brutal, and undeniable, and all of you who have been complaining will be quick to forgive being kept in the dark. Don't mistake the quiet for a lack of an efficacious business model.
When we are uplisted to NASDAQ, and PRED opens the floodgates with PRs, I think most of us (myself included) will literally be speechless. I've been told (again I will keep my source to myself) there are no less than 20 major PRs all set to go when this gets started. Let that sink in. 20.
My contact has been right across the board with what he said would come with PRED. Sometimes it took a little more time to get there than initially thought, but PRED has gotten there....every.....single....time.
Are you longs ready?! It's coming...
Read the 27 press releases over the last 9 months and educate yourself.
Stock going back to highs
I agree but in this case the person in question doesn’t seem to want to adhere to these principles
Maybe the stock market isn’t for you? Listening to stories and rumors isn’t the way to make investment decisions. You have to be willing to ride the highs and lows if your happy with your own DD. If you can’t or have time constraints then you shouldn’t be in it. Not a criticism, just a statement. Doesn’t help you now I know but worth bearing in mind he next time round .
Good luck whatever you do
Stock going up, no brainer
Every day the same, end of day hit just to drive it a few cents lower. All going to turn around soon but it’s funny, every day at 3-55 in with the small dump
Talk is cheap, company execution is all that matters. Message board chit chat either way won’t make a difference. Good fun times ahead
Then sell, don’t buy, so whatever
Board got zero shares, just warrants at above $2. Shares were performance based for hitting milestones which they obviously did. Not uncommon, performance based incentives are where it’s at
It’s really simple and if you look at the flagship deal, the shares issues were for meeting performance targets for sales. All there in black and white.
SG and A also increased as they almost doubled their workforce! And even with that they are cash flow positive! That’s even before their primary products and relationships come online
The point being made is that anyone who thought they were buying into a stem cell company is wrong. Stem cells is an incredibly volatile arena and is open is severe regulatory enforcement at any time. It’s the Wild West, PRED products are best in class however they are not the future of this company. We will not achieve a multi billion market cap due to stem cell revenues, it will be down to the next gen diagnostics and treatments. TMO are not involved because of stem cells! It’s a nice way of paying bills etc in the short term but the roll out of the TMO agreement for pred diagnostics worldwide is where it’s at
most are missing the point
Go read the press over the last year. Stem cell revenue being up isn’t the point. The future is the diagnostics, therapy’s and the use of their platform.
To date we know of endometriosis, preeclampsia, joint treatment, pain management plus much much more. Life sciences companies that have one all or nothing potential products trade at billions of dollars yet pred has multiple routes to market.
Add in the world class science team, world class board, world class attorneys and then you will understand where this is going.
As Thomas alluded to earlier in the week, the value here is the patents and their platform. Everyone wants instant gratification as that’s the story of the otc and how 95% of everyone is. This is a growing company doing good increasing revenues, cash flow positive with an incredible pipleline and because price is depressed the “management” aren’t doing their job keeping people on a message board happy! That’s not their job no matter how important we all think we are.
This company is substantially better now than it was at $6 but I didn’t hear anyone at $6 saying management are doing a terrible job! Nope, everyone caught up in the euphoria and patting themselves on the baby. The company doesn’t control share price, they control the fundamentals l.
They have released 27 pieces of fantastic news over the last nine months, yet most on here are still talking about stem cells. Go do some work and actually read them, you may surprise yourself and learn something
Last time I checked it’s a 24 hour day!
Also what are you waiting for? It’s an end of year report. It won’t say anything you don’t know already! Plus who’s been waiting for this day? Can you explain why this day is so important to you?
Green coming
All has to be reported by 5-30